Cerapedics Secures $19M Series C

Cerapedics Inc announced that it recently completed a Series C round of private equity financing totaling 19 million led by new investors MedImmune Ventures and CVF LLC an affiliate of Henry Crown and Company Existing investors including OrbiMed Advisors and NGN Capital also participated In conjunction with the financing Sam Wu M D , Ph D , Managing Director of MedImmune Ventures joined the Board of Directors

Proceeds will be used to support the company’s ongoing activities with its current Investigational Device Exemption IDE clinical trial in the United States studying its i-FACTOR peptide enhanced bone graft for cervical spine applications and prepare for commercialization upon FDA approval The proceeds will also allow Cerapedics to accelerate the development of next generation products and continue investments in sales and marketing to meet demand for the company’s i-FACTOR bone graft outside the United States

We are gratified with the response received from the financial community given the challenging economic environment present industry-wide It is a direct reflection of the merits of the clinically tested i-FACTOR product portfolio and the team we have put in place globally said Paul Mraz Cerapedics President and Chief Executive Officer Cerapedics is well-positioned to become a key player in the nearly 2 billion osteobiologics marketplace across spine trauma and orthopedic reconstruction worldwide ”

Andy Handwerker Chief Operating Officer at Cerapedics commented This financing is solid validation of our proposition to be the second premarket approval PMA designated osteobiologic product to address the spine market in the United States and the first to be indicated for use in the cervical spine Proceeds from this financing will allow Cerapedics to continue to grow sales strategically outside the USA and gather long-term follow-up data from numerous clinical studies for a variety of bone repair indications ”

Cerapedics also announced that the company earlier received agreement from the U S Food and Drug Administration FDA to proceed with a PMA modular submission for its ongoing IDE clinical trial studying i-FACTOR peptide enhanced bone graft in cervical spine fusion and has commenced that process

About Cerapedics Inc

Cerapedics a 2012 Colorado Companies to Watch COCTW winner is a privately held medical device company focused on developing and commercializing novel osteobiologic products based on its proprietary anorganic bone mineral ABM and synthetic small peptide P-15 technology platform for use in a wide variety of spine trauma and orthopedic surgical procedures i-FACTOR bone graft is the only biologic bone graft that utilizes a synthetic small peptide as an attachment factor intended to stimulate the natural bone healing process resulting in safe predictable bone formation at a fraction of the cost of growth factors

Cerapedics i-FACTOR bone graft received CE Mark in 2008 and has been utilized clinically in nearly 10,000 spine trauma and orthopedic surgeries worldwide Currently i-FACTOR bone graft is commercially available in both Putty and Flex flexible strip forms in over 25 countries outside the United States i-FACTOR bone graft is currently being evaluated in the United States FDA as part of an Investigational Device Exemption IDE clinical trial in the cervical spine

CAUTION i-FACTOR bone graft is not commercially available in the USA In the USA i-FACTOR bone graft is an investigational device limited by Federal Law USA to investigational use only

More information can be found at a href=”http://www cerapedics com target=”_blank”>www cerapedics com